New payment models may mean more of the people who need these treatments can get them.
The COVID pandemic is giving drug companies an opportunity to reset their image. So how did they get so big and their credibility sink so low?
If Big Pharma wants to achieve the ultimate image makeover, it must capitalize on the current public good will about its COVID-19 vaccines by prioritizing socially responsible practices.
COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed to adequately deal with.
Waiver talks might convince companies to focus on technology transfer and training, and let go of the plan to maximise patent-based revenues.
Despite some public virtue signalling, the Canadian government is not doing all it can to improve global access to COVID-19 vaccines. Canada has yet to announce its position on the WTO patent waiver.
A vaccination queue-jumping scandal in Peru has caused a massive uproar in the South American country. It could also be a wake-up call for all nations.
‘Orphan drugs’ with high price points are being tested as treatments for COVID-19. There’s a better way to spur low-cost innovation for new drugs.
A private market should have no place in the rollout of a COVID vaccine.
The funding, procurement, storage and distribution of a vaccine present huge challenges to all governments, including New Zealand’s.
Patients have a stake in the relationship between doctors and pharmaceutical companies, so the CMA’s current review of its guidelines for doctor/pharma interactions is everybody’s business.
Medical innovation is often accelerated in a time of crisis.
Health Canada devotes far more resources to getting new drugs onto the market compared to making sure that drugs already being sold are safe.
The UK is investing heavily in preparation for mass manufacturing of a working COVID-19 vaccine.
Toilet paper shortages were bad enough. A shortage of drugs during the COVID-19 pandemic would be worse. A provision in the Canadian government’s relief package aims to prevent that from happening.
Drug shortages occur regularly in the US, even in the best of times. The pharmaceutical supply chain embodies ‘just in time’ shipping and has little built-in redundancy.
Too often, pharmaceutical companies and device manufacturers exert influence in how their products are tested in the research phase and recommended in the clinic.
The government should work with drug companies, not against them.
The first study to assess the carbon footprint of the pharmaceutical industry finds that it is far from green.
Two community pharmacists suggest a way for improving the palatability of evidence-based universal pharmacare – for those working in health insurance, pharmacy and the pharmaceutical industry.